janus kinase (JAK) inhibitor - living meta-analysis of clinical studies

table network network 2

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only

	COVID-19 mild to moderate

	COVID-19 mild to moderate
janus kinase (JAK) inhibitor
tofacitinib	Murugesan

3 studies excluded by filtering options 1

6141	Rodriguez-Garcia, 2020	1	10	0		not a RCT	risk of bias not avaialble
6415	Cantini, 2020	2	31	0	excluded	not a RCT	risk of bias not avaialble
6430	Cantini, 2020	1	13	4		not a RCT	high risk of bias